Company History and Available Information For the transition period from __________ to __________ CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Research and development expenses consist of costs associated with our research activities, including the development of our drug candidates. Our research and development expenses consist of: Revenue. We had no revenue for each of the three months ended September 30, 2023 and 2022. Delaware 87-0652870 (State or other jurisdiction of (I.R.S. Employer incorpora ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2023 Earnings Conference Call. [Operator Instructions] I would no ...

UNITED STATES FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Table of Contents Washington, D.C. 20549 Or Commission file number: 001-36333 | --- | --- | |------------------------------------------------------------------------------|------------------------------------------| | Delaware | 87-0652870 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification N ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2023 Earnings Conference Call. At this time, all participants are in ...

FORM 10-Q For the transition period from __________ to __________ | --- | --- | |------------------------------------------------------------------------------|------------------------------------------| | Delaware | 87-0652870 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | Bellaire Boulevard, Suite 210, Bellaire, Texas | 77401 | | (Address of principal executive offices) | (Zip Code) | Name of each exchange on which registered Indicate by check ...

Bio-Path Holdings Inc. (NASDAQ:BPTH) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ET Company Participants Will O'Connor - Stern IR Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Laura Engel - Stonegate Capital Partners Jonathan Aschoff - ROTH Capital Partners Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only m ...

UNITED STATES (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36333 BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per shar ...

Bio-Path Holdings Inc. (NASDAQ:BPTH) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth Capital Partners Yi Chen - H.C. Wainwright Laura Engel - Stonegate Capital Partners Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2022 Earnings Conference Call. At ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-36333 Bio-Path Holdings, Inc. (Exact name of registrant as specified in its charter ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Yi Chen - H.C. Wainwright Jonathan Aschoff - Roth Capital Partners Operator Good morning ladies and gentlemen and welcome to the Bio-Path Holdings Second Quarter 2022 Earnings Conference Call. At this time all participants are in a l ...